Expression of the Cell Adhesion Molecule CD146/MCAM in Non-Small Cell Lung Cancer

Expression of MCAM is observed in a variety of human malignancies. We aimed to determine the rate of MCAM expression in our non‐small cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters and patient survival. 85 NSCLC were analysed immunohistochemically using a monoclonal MCAM antibody (clone N1238) on an NSCLC tissue micro array. The staining was semiquantitatively scored. We found MCAM expression in 51% of NSCLC, preferentially squamous cell carcinomas (p=0.004). No other correlations to tumour size, grade, or stage were found. Univariate survival analysis showed no significant differences of MCAM positive and negative tumours. In adenocarcinomas however, MCAM positivity was significantly associated with shorter patient survival (p=0.016). We conclude, that MCAM is expressed in a high proportion of NSCLC and might be predictive of shortened patient survival in adenocarcinomas of the lung. Colour figure can be viewed onhttp://www.esacp.org/acp/2003/25-2/kristiansen.htm.

Download Full-text

B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer

Journal of Clinical Pathology ◽

10.1136/jclinpath-2017-204860 ◽

2018 ◽

Vol 71 (7) ◽

pp. 642-647 ◽

Cited By ~ 4

Author(s):

Liuwei Gao ◽

Hua Zhang ◽

Bin Zhang ◽

Jinfang Zhu ◽

Chen Chen ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Disease Free Survival ◽

Small Cell ◽

Clinicopathological Parameters ◽

Small Cell Lung ◽

Nsclc Tissue ◽

Clinical Prognosis ◽

Nsclc Patients

ObjectiveThe aim of this study was to evaluate the expression of beta-1,3-N-acetylglucosaminyltransferase-3 (B3GNT3) in non-small cell lung cancer (NSCLC) patients and to investigate the relevance of B3GNT3 expression in tumour prognosis.MethodsIn this study, B3GNT3 expression was examined in five pairs of resectable NSCLC tissue by Western blot and in 42 pairs of resectable NSCLC tissue by quantitative real-time PCR (qRT-PCR). Immunohistochemistry and statistical analysis were performed to assess the relationship between B3GNT3 expression scores and clinicopathological parameters, as well as clinical prognosis in a retrospective cohort of 176 NSCLC patients.ResultsBoth B3GNT3 mRNA and protein expression levels were significantly higher in NSCLC tissue than in adjacent normal tissue. In the 176 NSCLC cases, a high B3GNT3 expression level was positively correlated with lymph node metastasis (P<0.001) and advanced TNM stage (P=0.043). Kaplan-Meier analysis indicated that patients with high B3GNT3 expression had significantly lower disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001) than those with low B3GNT3 expression. Moreover, in the multivariate analyses, B3GNT3 expression was an independent prognostic factor for DFS (HR 0.329, 95% CI 0.213 to 0.508, P<0.001) and OS (HR 0.383, 95% CI 0.249 to 0.588, P<0.001).ConclusionsOur study demonstrated that high expression of B3GNT3 was associated with unfavourable DFS and OS in NSCLC patients, suggesting that B3GNT3 might be a potential prognostic biomarker for NSCLC.

Download Full-text

CD10 Expression in Non-Small Cell Lung Cancer

Analytical Cellular Pathology ◽

10.1155/2002/781580 ◽

2002 ◽

Vol 24 (1) ◽

pp. 41-46 ◽

Cited By ~ 14

Author(s):

Glen Kristiansen ◽

Karsten Schlüns ◽

Yu Yongwei ◽

Manfred Dietel ◽

Iver Petersen

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Survival ◽

Clinical Stage ◽

Small Cell ◽

Clinicopathological Parameters ◽

Cancer Tissue ◽

Small Cell Lung ◽

Cd10 Expression

CD10 is a cell surface endopeptidase that inactivates various potentially growth stimulatory peptides. In lung cancer cell lines this downregulation has been associated with increased proliferation. Downregulation of CD10 in lung cancer tissue is described, suggesting a potential role in carcinogenesis and a possible use of CD10 as a prognostic marker. We aimed to determine the rate of CD10 expression in our non‐small cell lung cancer (NSCLC) collection and to clarify its correlation with clinicopathological parameters and patient survival. 114 NSCLC were analysed immunohistochemically using a monoclonal CD10 antibody (clone NCL‐CD10‐270) on an NSCLC tissue micro array. The staining was semiquantitatively scored. CD10 expression was observed in 19% of cases, without any significant association with tumour type, ‐size, ‐grading, nodal status, clinical stage, and patient survival time. We conclude that a diagnostic use of CD10 immunostaining in NSCLC is unlikely.

Download Full-text

P2.16-08 Influence of Tumour Location and Histological Sub-Type of Non-Small Cell Lung Cancer on Patient Survival

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.1483 ◽

2018 ◽

Vol 13 (10) ◽

pp. S833-S834 ◽

Cited By ~ 1

Author(s):

A. McWilliam ◽

A. Davey ◽

E. Vasquez Osorio ◽

M. Aznar ◽

C. Faivre-Finn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Survival ◽

Small Cell ◽

Small Cell Lung ◽

Tumour Location

Download Full-text

Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy

Radiotherapy and Oncology ◽

10.1016/j.radonc.2019.04.022 ◽

2019 ◽

Vol 137 ◽

pp. 71-76 ◽

Cited By ~ 3

Author(s):

Alan McWilliam ◽

Eliana Vasquez Osorio ◽

Corinne Faivre-Finn ◽

Marcel van Herk

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Survival ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer

Cancer Control ◽

10.1177/1073274820964783 ◽

2020 ◽

Vol 27 (1) ◽

pp. 107327482096478

Author(s):

Hao Ding ◽

Wei Wen ◽

Qingqing Ding ◽

Xin Zhao

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Normal Group ◽

Smoking History ◽

Clinicopathological Parameters ◽

Small Cell Lung ◽

Pathological Differentiation ◽

Efficacy Of Treatment

Objective: This study aims to determine the diagnosis and prediction value of serum miR-184 and miR-191 levels in patients with non-small-cell lung cancer (NSCLC). Methods: One hundred patients with NSCLC were enrolled (NSCLC group) and treated with gefitinib. In addition, 59 pneumonia cases (pneumonia group) and 51 healthy cases in the corresponding period (normal group) were included. Serum miR-184 and miR-191 expressions were detected by real-time quantitative polymerase chain reaction. Furthermore, the relationships between serum miR-184 and miR-191 expressions and clinicopathological parameters were analyzed. The use of serum miR-184 and miR-191 levels in the diagnosis of NSCLC and the prediction of treatment effectiveness and 3-year overall survival (OS) were assessed by the receiver operating characteristic curve. Hazard factors affecting the efficacy of treatment in patients with NSCLC were determined by logistic regression. Results: The serum levels of miR-184 in the NSCLC group were significantly lower than those in the pneumonia group and normal group, whereas miR-191 expression was significantly higher in the NSCLC group. Serum miR-184 and miR-191 levels were closely correlated with smoking history, the tumor node metastasis (TNM) stage, and the degree of pathological differentiation. The area under curve (AUC) of serum miR-184 combined with miR-191 in the diagnosis of patients in the NSCLC group and normal group, NSCLC group and pneumonia group, and the efficacy of treatment in patients with NSCLC was 0.925, 0.929, and 0.916, respectively. The AUC of serum miR-184 and miR-191 for the 3-year OS in patients with NSCLC was 0.869 and 0.879, respectively. Smoking history, the degree of pathological differentiation, local treatment, miR-184, and miR-191 were independent risk factors that affected treatment efficacy. Conclusion: Serum miR-184 and miR-191 levels can potentially be used as molecular markers to diagnose and predict the curative effect of treatment in patients with NSCLC.

Download Full-text